Abstract: Disclosed is an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, the immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which an antigenic peptide is covalently bound to a single-stranded polynucleotide or polynucleotide derivative. Also disclosed is a pharmaceutical composition comprising said immunity-inducing agent.

Abstract: A population of ?-1,3-glucan/nucleic acid complexes, each of which contains ?-1,3-glucan and a nucleic acid containing a homo-polynucleotide that binds to ?-1,3-glucan via a hydrogen bond, and has a triple helical structure consisting of two ?-1,3-glucan chains and one nucleic acid chain containing the homo-polynucleotide that binds to ?-1,3-glucan via a hydrogen bond contained in the nucleic acid, where 30% or more of the ?-1,3-glucan/nucleic acid complexes contained in the population satisfy the following conditions: (i) they are homogeneous in the length of the homo-polynucleotide contained in the nucleic acid containing a homo-polynucleotide that bind to ?-1,3-glucan via a hydrogen bond constituting the complex, and (ii) the molecular number of the nucleic acid(s) containing a homo-polynucleotide that binds to ?-1,3-glucan via a hydrogen bond contained in one molecule of the complex is selected from the group consisting of 1, 2 and 3.

Abstract: Disclosed is an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, the immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which an antigenic peptide is covalently bound to a single-stranded polynucleotide or polynucleotide derivative. Also disclosed is a pharmaceutical composition comprising said immunity-inducing agent.

Abstract: The present invention provides an immunity-inducing agent comprising a polynucleotide-peptide conjugate or a pharmaceutically acceptable salt thereof as an active component, wherein the polynucleotide-peptide conjugate consists of: a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif; a peptide; and a spacer which is covalently bonded at one end thereof to the polynucleotide or polynucleotide derivative and covalently bonded at the other end thereof to the peptide, wherein the peptide is a peptide modified by substituting one or more contiguous amino acids at the N-terminus of an MHC-binding peptide with an amino acid having a reactive functional group which allows for the formation of a covalent bond with the spacer, wherein the one or more contiguous amino acids contain no anchor residues for MHC binding.

Abstract: The present invention provides an immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide, as well as a pharmaceutical composition comprising said immunity-inducing agent.

Abstract: A biological data obtaining device includes a storage unit, a first generation unit, and a second generation unit. The storage unit is configured to store time-series data in which first to Nth distance-based fluctuation data are arranged. The first to Nth distance-based fluctuation data are obtained based on reflected waves which are reflected from a living body at different times, wherein nth distance-based fluctuation data indicates changes in signal strength with respect to distance. The first generation unit is configured to generate time-based fluctuation data by performing strength obtaining process. The strength obtaining process includes obtaining one corresponding strength information, wherein the one corresponding strength information is a signal strength based on reflected waves from a predetermined detection part of the living body. The second generation unit is configured to generate biological data of the detection part of the living body based on the time-based fluctuation data.

Abstract: Disclosed is an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, the immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which an antigenic peptide is covalently bound to a single-stranded polynucleotide or polynucleotide derivative. Also disclosed is a pharmaceutical composition comprising said immunity-inducing agent.

Abstract: A method for producing lithium manganese oxide that is a precursor of a lithium adsorbent under atmospheric pressure is provided. The method for producing a precursor of a lithium adsorbent comprises tire following steps (1) to (3): (1) A 1st mixing step of mixing a manganese salt and alkali hydroxide, so as to obtain a 1st slurry containing manganese hydroxide; (2) a 2nd mixing step of adding lithium hydroxide to the 1st slurry and then mixing the mixture to obtain a 2nd slurry; and (3) an oxidation step of adding an oxidizing agent to the 2nd slurry, so as to obtain a precursor of a lithium adsorbent. The method for producing a precursor of a lithium adsorbent comprises these steps, so that a precursor of a lithium adsorbent can be produced under atmospheric pressure. Therefore, a precursor of a lithium adsorbent can be produced at a limited cost.

Abstract: An organic wastewater treatment method that includes a raw sludge removal step, a raw sludge concentration step, a biological treatment step, an excess sludge separation step, an excess sludge concentration step, a sludge mixing step, and a methane fermentation treatment step. The treatment method further includes a sterilization step for heating and sterilizing the concentrated excess sludge upstream of the sludge mixing step. At least one among: (1) the temperature to which the concentrated excess sludge is heated during sterilization, (2) the concentration of concentrated raw sludge and/or the concentration of the concentrated excess sludge, and (3) the mixture ratio between the concentrated raw sludge and the concentrated excess sludge is adjusted according to the fluctuation in the amount of raw sludge generated and the amount of the excess sludge generated, and the temperature of the mixed sludge is controlled to a temperature suited for methane fermentation.

Abstract: An organic wastewater treatment method that includes a raw sludge removal step, a raw sludge concentration step, a biological treatment step, an excess sludge separation step, an excess sludge concentration step, a sludge mixing step, and a methane fermentation treatment step. The treatment method further includes a sterilization step for heating and sterilizing the concentrated excess sludge upstream of the sludge mixing step. At least one among: (1) the temperature to which the concentrated excess sludge is heated during sterilization, (2) the concentration of concentrated raw sludge and/or the concentration of the concentrated excess sludge, and (3) the mixture ratio between the concentrated raw sludge and the concentrated excess sludge is adjusted according to the fluctuation in the amount of raw sludge generated and the amount of the excess sludge generated, and the temperature of the mixed sludge is controlled to a temperature suited for methane fermentation.